| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2004 | DE10210195A1 Derivate von Aza-Spiroverbindungen Derivatives of aza-spiro compounds |
| 01/22/2004 | CA2843044A1 A process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid |
| 01/22/2004 | CA2833808A1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 01/22/2004 | CA2805600A1 Medicaments containing vardenafil hydrochloride trihydrate |
| 01/22/2004 | CA2743341A1 Drugs for treating or preventing brain injury and a method of screening the same |
| 01/22/2004 | CA2621093A1 Production of polyketides and other natural products |
| 01/22/2004 | CA2509821A1 3-phenyl analogs of toxoflavine as kinase inhibitors |
| 01/22/2004 | CA2495432A1 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| 01/22/2004 | CA2493675A1 Genes |
| 01/22/2004 | CA2493374A1 Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| 01/22/2004 | CA2493373A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 01/22/2004 | CA2493372A1 Cinnamide derivatives |
| 01/22/2004 | CA2493111A1 Diagnosis and prevention of cancer cell invasion |
| 01/22/2004 | CA2493004A1 Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them |
| 01/22/2004 | CA2492781A1 Medicinal composition for mitigating blood lipid or lowering blood homocystein |
| 01/22/2004 | CA2492772A1 Activated checkpoint therapy and methods of use thereof |
| 01/22/2004 | CA2492743A1 Antimicrobial oxazolidinones, process of their preparation, and pharmaceutical compositions containing them |
| 01/22/2004 | CA2492725A1 Medicinal composition for drug-induced neuropathy |
| 01/22/2004 | CA2492722A1 Production method of coated preparations |
| 01/22/2004 | CA2492694A1 Therapeutic or prophylactic agent for preventing nausea and vomiting |
| 01/22/2004 | CA2492669A1 Novel indoline compound and medicinal use thereof |
| 01/22/2004 | CA2492593A1 Compounds, compositions, and methods employing same |
| 01/22/2004 | CA2492561A1 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | CA2492554A1 Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
| 01/22/2004 | CA2492488A1 Liquid dosage compositions of stable nanoparticulate active agents |
| 01/22/2004 | CA2492445A1 Indole-3-sulphur derivatives |
| 01/22/2004 | CA2492433A1 Organic amine salts of poorly soluble probucol esters and ethers |
| 01/22/2004 | CA2492430A1 Phenylalanine enamide derivatives |
| 01/22/2004 | CA2492387A1 Combination of an allosteric carboxylic of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/22/2004 | CA2492381A1 Phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors |
| 01/22/2004 | CA2492379A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| 01/22/2004 | CA2492374A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea |
| 01/22/2004 | CA2492373A1 Cephalosporins |
| 01/22/2004 | CA2492368A1 Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same |
| 01/22/2004 | CA2492355A1 Method for diagnosis of intestinal-type gastric tumors |
| 01/22/2004 | CA2492330A1 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 01/22/2004 | CA2492273A1 3, 10, and 12a substituted tetracycline compounds |
| 01/22/2004 | CA2492266A1 Process for controlling the hydrate mix of a compound |
| 01/22/2004 | CA2492175A1 Combination of chemotherapeutic drugs for increasing antitumor activity |
| 01/22/2004 | CA2492164A1 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | CA2492100A1 Substituted 2-alkylamine nicotinic amide derivatives and use there of |
| 01/22/2004 | CA2492093A1 Topical treatment of skin diseases |
| 01/22/2004 | CA2492083A1 N-sulfonylpiperidines as metalloproteinase inhibitors (tace) |
| 01/22/2004 | CA2492059A1 Combinations of drugs for the treatment of neoplasms |
| 01/22/2004 | CA2492046A1 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 01/22/2004 | CA2492045A1 Substituted amine derivatives and methods of use |
| 01/22/2004 | CA2492022A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds |
| 01/22/2004 | CA2491820A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/22/2004 | CA2491797A1 Gastrointestinal compositions |
| 01/22/2004 | CA2491721A1 Gastrointestinal compositions comprising gaba derivatives |
| 01/22/2004 | CA2491655A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations |
| 01/22/2004 | CA2491422A1 Novel macrocycles for the treatment of cancer diseases |
| 01/22/2004 | CA2491235A1 Chromosome 3, 5 and 11 genes involved in premature canities |
| 01/22/2004 | CA2491223A1 Chromosome 6 and 9 genes involved in premature canities |
| 01/22/2004 | CA2491183A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 01/22/2004 | CA2491077A1 Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders |
| 01/22/2004 | CA2490818A1 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/22/2004 | CA2490666A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 01/22/2004 | CA2490468A1 Novel thiophene acyl hydrazino derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use |
| 01/22/2004 | CA2490308A1 Use of amino acids for treatment of various conditions |
| 01/22/2004 | CA2489790A1 3-furanyl analogs of toxoflavine as kinase inhibitors |
| 01/22/2004 | CA2489722A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| 01/21/2004 | EP1382969A1 Diagnosis and prevention of cancer cell invasion |
| 01/21/2004 | EP1382687A1 Process for producing isomaltose and use thereof |
| 01/21/2004 | EP1382679A2 Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
| 01/21/2004 | EP1382662A1 Sterol compositions, fat compositions containing the same and foods |
| 01/21/2004 | EP1382616A2 Pharmaceutical composition for use in the treatment of abnormalities associated with the activity of a human Y5-receptor |
| 01/21/2004 | EP1382608A1 Sulfate of cephem compound |
| 01/21/2004 | EP1382607A2 Prenyl transferase inhibitors |
| 01/21/2004 | EP1382606A2 8-azabicyclo[3.2.1]octane derivatives and their use as anticholinergics |
| 01/21/2004 | EP1382605A2 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands |
| 01/21/2004 | EP1382604A1 Quinoline derivative having azolyl group and quinazoline derivative |
| 01/21/2004 | EP1382603A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF |
| 01/21/2004 | EP1382598A1 Novel heterocyclic derivatives |
| 01/21/2004 | EP1382597A2 Steroid receptor modulator compounds and methods |
| 01/21/2004 | EP1382351A1 Combination therapy of agiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovasuclar disease |
| 01/21/2004 | EP1382349A1 Supplementary immunotherapeutics to be used after lung cancer removal |
| 01/21/2004 | EP1382344A1 Bactericidal disinfectant, antibacterial drug, and antibacterial material |
| 01/21/2004 | EP1382343A1 Combination therapy to treat hepatitis B virus |
| 01/21/2004 | EP1382342A1 Use of compositiosn comprising glycyrrhetinic acid and salicylic acid for acne treatment |
| 01/21/2004 | EP1382341A1 Use of compositions comprising glycyrrhetinic acid and benzoyl peroxide for acne treatment |
| 01/21/2004 | EP1382340A1 Therapeutic uses of dehydroepiandrosterone for treating diminished libido and osteoporosis |
| 01/21/2004 | EP1382339A1 Compositions containing pyrrolo [2,3-d] pyrimidine derivatives |
| 01/21/2004 | EP1382338A1 Controlled release tablet comprising tilidine and a photoprotectant |
| 01/21/2004 | EP1382337A1 Novel formulation containing paroxetine |
| 01/21/2004 | EP1382336A1 Abc expression promoters |
| 01/21/2004 | EP1382335A1 Medicines |
| 01/21/2004 | EP1382334A1 Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
| 01/21/2004 | EP1382333A2 Use of beta 3 adrenergic receptor agonists in the treatment of dysuria |
| 01/21/2004 | EP1382332A1 Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent |
| 01/21/2004 | EP1382330A1 Aqueous-Based pharmaceutical composition |
| 01/21/2004 | EP1382329A1 Compositions for photoprotection comprising a flavonoid |
| 01/21/2004 | EP1382263A2 Use of calcium in acidic oral compositions for the reduction of tooth erosion caused by acid |
| 01/21/2004 | EP1381867A2 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls |
| 01/21/2004 | EP1381839A2 Method of imaging cell death in vivo |
| 01/21/2004 | EP1381691A2 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression |
| 01/21/2004 | EP1381686A2 Inactivation of genes of the mep pathway |
| 01/21/2004 | EP1381684A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/21/2004 | EP1381620A2 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
| 01/21/2004 | EP1381615A2 ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H- 1,4]DIOXINO 2,3-e]INDOLE |